Area of research
Microbiology · Epidemiology · mRNA vaccine adjuvant
Research interest
Dr. Rappuoli introduced several novel scientific concepts, the names of which have become well known. Examples are the concept that bacterial toxins can be detoxified by manipulation of their genes (genetic detoxification, 1987), the concept that microbes are better studied in the context of the cells they interact with instead of artificial laboratory conditions (cellular microbiology, 1996), the use of genomes to develop new vaccines (reverse vaccinology, 2000), the observation that the genome of a species (pangenome, 2005) is larger than the genome of an organism of the same species. Several molecules he worked with became part of licensed vaccines. He characterized a molecule, CRM197, that today is the most widely used carrier for vaccines against H. influenzae, N.
Broadly protective mucosal vaccination in the respiratory tract
Vaccinology in the artificial intelligence era.
Antigen-agnostic identification of poxvirus broadly neutralizing antibodies targeting OPG153.
Challenges and opportunities in mRNA vaccine development against bacteria.
Monoclonal antibodies protect against pandrug-resistant Klebsiella pneumoniae.
The power of microbial life for the transformation towards a sustainable planet: key messages from the 2024 IUMS Congress in Florence, the city of the Renaissance.
Human monoclonal antibodies targeting subdominant meningococcal antigens confer cross-protection against gonococcus.
The Story behind the Science: The discovery of <i>Helicobacter pylori</i> CagA, the first tumorigenic bacterial protein.
Microbes without borders: uniting societies for climate action.
A multifunctional anti-O-Antigen human monoclonal antibody protects against <i>Shigella sonnei</i> infection in vivo.
Microbes without borders: uniting societies for climate action.
Antigen-agnostic identification of poxvirus broadly neutralizing antibodies targeting OPG153
Scientists' call to action: Microbes, planetary health, and the Sustainable Development Goals.
Transforming vaccinology.
Licensed H5N1 vaccines generate cross-neutralizing antibodies against highly pathogenic H5N1 clade 2.3.4.4b influenza virus.
4CMenB journey to the 10-year anniversary and beyond.
Safety and Immunogenicity of a 4-Component Generalized Modules for Membrane Antigens Shigella Vaccine in Healthy European Adults: Randomized, Phase 1/2 Study.
Discovery and characterization of a pan-betacoronavirus S2-binding antibody.
SARS-CoV-2 JN.1 variant evasion of IGHV3-53/3-66 B cell germlines.
High-resolution map of the Fc functions mediated by COVID-19-neutralizing antibodies.
Antigenic sin and multiple breakthrough infections drive converging evolution of COVID-19 neutralizing responses.
Standing the test of COVID-19: charting the new frontiers of medicine
Vaccination for healthy aging.
The economic case for scaling up health research and development: Lessons from the COVID-19 pandemic.
Functional diversification of innate and inflammatory immune responses mediated by antibody fragment crystallizable activities against SARS-CoV-2.
Neisserial adhesin A (NadA) binds human Siglec-5 and Siglec-14 with high affinity and promotes bacterial adhesion/invasion.
Deep-learning image analysis for high-throughput screening of opsono-phagocytosis-promoting monoclonal antibodies against Neisseria gonorrhoeae.
B cell maturation restored ancestral germlines to control Omicron BA.2.86
Genetic characterization and estimated 4CMenB vaccine strain coverage of 284 <i>Neisseria meningitidis</i> isolates causing invasive meningococcal disease in Argentina in 2010-2014.
The evolving landscape of live attenuated COVID-19 vaccines.